1. Giordano,A.and N. Normanno,Breast cancer in the post genomic era.2009: Springer Science & Business Media. [ DOI:10.1007/978-1-60327-945-1] 2. Hosseinzadeh M, Eivazi Ziaei J, Mahdavi N, Aghajari P, Vahidi M, Fateh A. Risk factors for breast cancer in Iranian women :a hospital based case control study in Tabriz, Iran. J Breast Cancer 2014;17:236-243. [ DOI:10.4048/jbc.2014.17.3.236] 3. Dumitrescu R, Cotarla I. Understanding breast cancer risk .Where do we stand in 2005. J Cell Mol Med 2005;9:208-221. [ DOI:10.1111/j.1582-4934.2005.tb00350.x] 4. DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64:52-62. [ DOI:10.3322/caac.21203] 5. Sadjadi A, Nouraie M, Ghorbani A, Alimohammadian M, Malekzadeh R. Epidemiology of breast cancer in the Islamic Republic of Iran: first results from a population-based cancer registry. East Mediterr Health J 2009;15:1426-31. 6. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374-403. [ DOI:10.1016/j.ejca.2012.12.027] 7. Ebrahimi,M, M.Vahdaninia, A. Montazeri. Risk factors for breast cancer in Iran : a case control study. Breast Cancer Res 2002;4: r10. [ DOI:10.1186/bcr454] 8. Simon R. Clinical trial designs for evaluating the medical utility of prognostic and predictive Biomarkers in oncology. Pre Med 2010;7:33-47. [ DOI:10.2217/pme.09.49] 9. Shiovitz S, Korde LA. Genetics of breast cancer: a topic in evolution. Ann Oncol. 2015;26:1291-99. [ DOI:10.1093/annonc/mdv022] 10. Simon R. Sensitivity. Specificity PPV and NPV for predictive biomarkers. J Natl Cancer Inst 2015;107: pii: djv153. [ DOI:10.1093/jnci/djv153] 11. Siegel R, Naishadham D, Jemal A. Cancer Statistics, 2013. CA Cancer J Clin 2013;63:11-30. [ DOI:10.3322/caac.21166] 12. Hayes DF. Biomarker Validation and testing .Molon col 2015;9:960-66. [ DOI:10.1016/j.molonc.2014.10.004] 13. Xia B, Sheng Q, Nakanishi K. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol cell 2006;22:719-29. [ DOI:10.1016/j.molcel.2006.05.022] 14. Zhang F, Ma J,Wu J. PALB2 links BRCA1 and BRCA2 in the DNA-damage response Curr Biol. 2009;19:524. [ DOI:10.1016/j.cub.2009.02.018] 15. Casadei S, Norquist BM, Walsh T. Contribution of inherited mutations in the BRCA2 interacting protein PALB2 to familial breast cancer. Cancer Res. 2011; 71-2222-29. 16. Shirley M.H.SY. PALB2 is an integral component of the BRCA complex required for homologous recombination repair 5. Proc Natl Acad Sci U S A 2009; 106:7155-60. [ DOI:10.1073/pnas.0811159106] 17. Bowman-Colin C, Xia B, Bunting S, Klijn C, Drost R, Bouwman P, et al. Palb2 synergizes with Trp53 to suppress mammary tumor formation in a model of inherited breast cancer. Proc Natl Acad Sci U S A. 2013;110:8632-37. [ DOI:10.1073/pnas.1305362110] 18. Monteiro LJ, Khongkow P, Kongsema M, Morris JR, Man C, Weekes D, et al. The Forkhead Box M1 protein regulates BRIP1 expression and DNA damage repair in epirubicin treatment. Oncogene. 2013;32:4634-45. [ DOI:10.1038/onc.2012.491] 19. Rohanizadegan M. Analysis of circulating tumor DNA in breast cancer as a diagnostic and prognostic biomarker. Cancer Genet. 2018 pii: S2210-7762:30292-2. 20. Loke SY, Lee ASG. The future of blood-based biomarkers for the early detection of breast cancer. Eur J Cancer. 2018;92:54-68. [ DOI:10.1016/j.ejca.2017.12.025] 21. Sauter ER. Reliable Biomarkers to Identify New and Recurrent Cancer. Eur J Breast Health. 2017;13:162-167. [ DOI:10.5152/ejbh.2017.3635] 22. Boschetti E, D'Amato A, Candiano G, Righetti PG. Protein biomarkers for early detection of diseases: The decisive contribution of combinatorial peptide ligand libraries. J Proteomics. 2017: S1874-3919:30285-3. 23. Bahrami A, Aledavood A, Anvari K, Hassanian SM, Maftouh M, Yaghobzade A, et al. The prognostic and therapeutic application of microRNAs in breast cancer: Tissue and circulating microRNAs. J Cell Physiol. 2018;233:774-786. [ DOI:10.1002/jcp.25813] 24. Nassar FJ, Nasr R, Talhouk R. MicroRNAs as biomarkers for early breast cancer diagnosis, prognosis and therapy prediction. Pharmacol Ther. 2017;172:34-49. [ DOI:10.1016/j.pharmthera.2016.11.012] 25. Iranshahi N, Zafari P, Yari KH, Alizadeh E. The most common genes involved in epigenetics modifications among Iranian patients with breast cancer: A systematic review. Cell Mol Biol (Noisy-le-grand). 2016;31;62:116-122. 26. Mistry DA, French PW. Circulating Phospholipids as Biomarkers of Breast Cancer: A Review. Breast Cancer (Auckl). 2016;10:191-196. [ DOI:10.4137/BCBCR.S40693] 27. Thompson ER, Rowley SM, Li N, McInerny S, Devereux L, Wong-Brown MW, et al. Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care. J Clin Oncol. 2016;34:1455-59. [ DOI:10.1200/JCO.2015.63.7454] 28. Zhao LL, Zhang T, Liu BR, Liu TF, Tao N, Zhuang LW. Construction of pancreatic cancer double-factor regulatory network based on chip data on the transcriptional level. Mol Biol Rep. 2014;41:2875-83. [ DOI:10.1007/s11033-014-3143-4] 29. Raman D, Foo CH, Clement MV, Pervaiz S. Breast Cancer: A Molecular and Redox Snapshot. Antioxid Redox Signal. 2016;25:337-70. [ DOI:10.1089/ars.2015.6546]
|